Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"PFIZER NEW ZEALAND LIMITED, Clinician",Inotuzumab,"Acute lymphoblastic leukaemia (ALL), eligible and ineligible for transplant, relapsed/refractory CD22-positive, adults",Inotuzumab (Besponsa),,Hospital,Oncology Agents and Immunosuppressants
